Wave Life Sciences Ltd (WVE)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Wave Life Sciences Ltd.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 5.50 $ — 0% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 127.0% passed
- More than 10% revenue growth is expected for the coming year -12.9% failed
- Share count grows by less than 3% a year 28.8% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -501.0% failed
- Gross margin at 40% or higher and without meaningful erosion 79.3% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 584 m net cash passed
- Operating cash flow covers the profits of the last three years 1 m failed
- Return on capital at 15% or higher, or up versus two years ago -39.6% failed
- Insiders hold at least 10% or are net buyers 15.9% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 256.9% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 13
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.15 | -1.22 – -1.02 | 55 | 4.7% | 8 |
| 12/31/2027 | -1.14 | -1.68 – -0.03 | 50 | 1.0% | 12 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.17 | – | 84 | 188.20 | 34.90 | -44 | -44 |
| 2025: Q1 | -0.29 | – | 9 | -26.80 | -510.90 | -63 | -63 |
| 2025: Q2 | -0.31 | – | 9 | -55.80 | -580.20 | -46 | -46 |
| 2025: Q3 | -0.32 | – | 8 | – | -707.80 | -45 | -45 |
| 2025: Q4 | -0.30 | -273.90 | 17 | -79.40 | -308.40 | -32 | -32 |
| 2026: Q1 | -0.13 | – | 38 | 316.90 | -68.20 | -60 | -60 |
| 2026: Q2 | -0.34 | -9.70 | 2 | -73.60 | -3,017.40 | -54 | -55 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1 | -55 | -55 | -2.43 | -32 | 135 | 165 |
| 2017 | 4 | -103 | -102 | -3.85 | -84 | 140 | 182 |
| 2018 | 14 | -160 | -147 | -5.06 | -23 | 73 | 296 |
| 2019 | 16 | -208 | -194 | -5.72 | -188 | 72 | 284 |
| 2020 | 20 | -153 | -150 | -3.82 | -116 | 91 | 279 |
| 2021 | 41 | -127 | -122 | -2.36 | -89 | 33 | 207 |
| 2022 | 4 | -163 | -162 | -2.05 | -128 | -45 | 146 |
| 2023 | 113 | -68 | -58 | -0.54 | -19 | 40 | 275 |
| 2024 | 108 | -110 | -97 | -0.70 | -151 | 210 | 352 |
| 2025 | 43 | -215 | -204 | -1.21 | -187 | 526 | 639 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Wave Life Sciences Ltd., ein Biotechnologieunternehmen in der klinischen Phase, entwirft, entwickelt und vermarktet Ribonukleinsäure-(RNA)-Medikamente über PRISM, eine Entdeckungs- und Arzneimittelentwicklungsplattform.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 317 |
| Headquarters | Singapore, Singapore |
| Address | Marina One East Tower, 018936 Singapore, Singapore |
| Phone | 65 6236 3388 |
| Website | wavelifesciences.com |
| IPO Date | 11. Nov 2015 |
| ISIN | USY953081053 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Paul B. Bolno M.B.A., M.D. | President, CEO & Director | 1974 |
| Gregory L. Verdine Ph.D. | Founder & Director | 1959 |
| Kyle B. Moran CFA | CFO & Principal Accounting Officer | 1971 |
| Chandra Vargeese Ph.D. | Chief Technology Officer | 1961 |
| Christopher Francis Ph.D. | Senior VP of Corporate Development & Head of Emerging Areas | 1978 |
| Erik Ingelsson M.D., Ph.D. | Chief Scientific Officer | – |
| Kate Rausch | Head of Investor Relations | – |
| Linda Rockett J.D. | Senior VP & General Counsel | – |
| Daryn Lewis | Senior VP & Head of Human Resources | – |
| Sridhar Vaddeboina M.B.A., Ph.D. | Senior Vice President of Chemistry, Manufacturing & Controls | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.